Tokyo, Sept. 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059188) titled 'Exploratory Study on the Risk Factors and Prevention of Lipohypertrophy at Injection Sites of Insulin and GLP-1 Receptor Agonists in People with Type 2 Diabetes: A Collaborative Study with Certified Nurses in Diabetes Nursing' on Sept. 25.
Study Type:
Observational
Primary Sponsor:
Institute - National Hospital Organization Kyoto Medical Center
Condition:
Condition - type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to clarify the actual status of induration associated with subcutaneous injections of insulin or GLP-1 receptor agonists in patients with type 2 diabetes, and to explore its contributing factors and the relationship with nurses guidance and education. In particular, it will examine how injection site rotation practices, patients self-awareness, and interventions by certified diabetes nurse specialists influence the presence and severity of induration
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 4
years-old
Gender - Male and Female
Key inclusion criteria - 1) Age 4 or older
2) Type 2 diabetes
3) Receiving insulin therapy
Key exclusion criteria - Individuals deemed unsuitable for participation in the study by the principal investigator or co-investigators
Target Size - 200
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 08 Month 19 Day
Date of IRB - 2025 Year 08 Month 19 Day
Anticipated trial start date - 2025 Year 09 Month 09 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067318
Disclaimer: Curated by HT Syndication.
